Tag Archive for: BioPharma

Poolbeg Pharma plc – Positive Conclusion Reached in Immunomodulator I Patent Opposition

/in

29 September 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces that further to its announcement on 19 September 2023, the oral opposition hearing scheduled by the European Patent Office (‘EPO’) relating to the challenge to the Company’s European patent (Immunomodulator I), has been cancelled. This favourably […]

Read more

Poolbeg Pharma plc – Immunomodulator I Patent Portfolio Strengthened

/in

20 September 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces that it has received a notice of allowance from the Japanese Patent Office in relation to its Immunomodulator I patent application. Read more…

Read more

Brace yourself for the busiest week in biopharma!

/in

More than hangover-busting aspirin will be in order at the biopharma industry’s biggest week in London.  The capital will host a gruelling conference double header, beginning with the LSX Inv€$tival Showcase on Monday 13th November, followed by the Jefferies London Healthcare Conference on Tuesday 14th November.  With investors and biopharma business leaders descending on the […]

Read more

Poolbeg Pharma plc – Interim results for the six months to 30 June 2023

/in

Significant progress made and well positioned for future growth  13 September 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces its unaudited interim results for the six months to 30 June 2023. Read more…

Read more

Lytix Biopharma announces completion of patient recruitment in the ATLAS-IT-05 trial

/in

Oslo, 29 August 2023. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, announces that it has completed recruitment of 20 patients in the ATLAS-IT-05 trial – a trial evaluating LTX-315, Lytix’s lead drug candidate. Read more…..

Read more